TY  - JOUR
AU  - Kim, Min P.
AU  - Swisher, Stephen G.
PY  - 2019
TI  - Heterogeneity of stage IIIA leads to difficulty in determining optimal treatment
JF  - Journal of Thoracic Disease; Vol 11, Supplement 15 (September 29, 2019): Journal of Thoracic Disease
Y2  - 2019
KW  - 
N2  - A recent PACIFIC trial shows that patients with clinical stage IIIA non-small cell lung cancer who can’t have surgical resection have an overall survival rate of 66% at 24 months with chemoradiation therapy followed by immunotherapy.
UR  - https://jtd.amegroups.org/article/view/31310